146 related articles for article (PubMed ID: 37221284)
1. Does older age justify chlorambucil control arms for chronic lymphocytic leukemia clinical trials: a SEER-Medicare analysis.
Diamond A; Vu L; Bensken WP; Koroukian SM; Caimi PF
Leukemia; 2023 Jul; 37(7):1558-1560. PubMed ID: 37221284
[No Abstract] [Full Text] [Related]
2. Gingival Leukemic Infiltration in Chronic Lymphocytic Leukemia.
Kacem K; Zriba S; Saadi M; Doghri R
Turk J Haematol; 2019 Nov; 36(4):278-279. PubMed ID: 31234618
[No Abstract] [Full Text] [Related]
3. Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification.
Laurenti L; Innocenti I; Autore F; Ciolli S; Mauro FR; Mannina D; Del Poeta G; D'Arena G; Massaia M; Coscia M; Molica S; Pozzato G; Efremov DG; Vannata B; Marasca R; Galieni P; Cuneo A; Orlando S; Piciocchi A; Boncompagni R; Vincelli D; Liberati AM; Russo F; Foá R
Haematologica; 2017 Sep; 102(9):e352-e355. PubMed ID: 28596282
[No Abstract] [Full Text] [Related]
4. Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.
Seiter K; Mamorska-Dyga A
Clin Interv Aging; 2015; 10():951-61. PubMed ID: 26109852
[TBL] [Abstract][Full Text] [Related]
5. Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database.
Satram-Hoang S; Reyes C; Hoang KQ; Momin F; Skettino S
Ann Hematol; 2014 Aug; 93(8):1335-44. PubMed ID: 24638841
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.
Langerak AW; Ritgen M; Goede V; Robrecht S; Bahlo J; Fischer K; Steurer M; Trněný M; Mulligan SP; Mey UJM; Trunzer K; Fingerle-Rowson G; Humphrey K; Stilgenbauer S; Böttcher S; Brüggemann M; Hallek M; Kneba M; van Dongen JJM
Blood; 2019 Jan; 133(5):494-497. PubMed ID: 30455380
[No Abstract] [Full Text] [Related]
7. Real-world treatment and outcomes among older adults with chronic lymphocytic leukemia before the novel agents era.
Mato A; Jahnke J; Li P; Mehra M; Ladage VP; Mahler M; Huntington S; Doshi JA
Haematologica; 2018 Oct; 103(10):e462-e465. PubMed ID: 29700170
[No Abstract] [Full Text] [Related]
8. Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia.
Goede V; Eichhorst B; Fischer K; Wendtner CM; Hallek M
Leuk Lymphoma; 2015 Jun; 56(6):1585-92. PubMed ID: 25219593
[TBL] [Abstract][Full Text] [Related]
9. Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology Annual Meeting.
Clin Adv Hematol Oncol; 2019 Jan; 17 Suppl 1(1):1-24. PubMed ID: 31545307
[No Abstract] [Full Text] [Related]
10. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies.
Woyach JA; Ruppert AS; Rai K; Lin TS; Geyer S; Kolitz J; Appelbaum FR; Tallman MS; Belch AR; Morrison VA; Larson RA; Byrd JC
J Clin Oncol; 2013 Feb; 31(4):440-7. PubMed ID: 23233702
[TBL] [Abstract][Full Text] [Related]
11. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
Ladyzynski P; Molik M; Foltynski P
Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118
[TBL] [Abstract][Full Text] [Related]
12. Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil.
Tam C; Kuss B; Opat S; Boulos J; Marlton P
Intern Med J; 2017 Jul; 47 Suppl 4():5-10. PubMed ID: 28685928
[TBL] [Abstract][Full Text] [Related]
13. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
Rai KR; Peterson BL; Appelbaum FR; Kolitz J; Elias L; Shepherd L; Hines J; Threatte GA; Larson RA; Cheson BD; Schiffer CA
N Engl J Med; 2000 Dec; 343(24):1750-7. PubMed ID: 11114313
[TBL] [Abstract][Full Text] [Related]
14. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study.
Michallet AS; Aktan M; Hiddemann W; Ilhan O; Johansson P; Laribi K; Meddeb B; Moreno C; Raposo J; Schuh A; Ünal A; Widenius T; Bernhardt A; Kellershohn K; Messeri D; Osborne S; Leblond V
Haematologica; 2018 Apr; 103(4):698-706. PubMed ID: 29419437
[TBL] [Abstract][Full Text] [Related]
15. Chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL) - a systematic review and meta-analysis of randomized trials.
Vidal L; Gurion R; Ram R; Raanani P; Bairey O; Robak T; Gafter-Gvili A; Shpilberg O
Leuk Lymphoma; 2016 Sep; 57(9):2047-57. PubMed ID: 26980554
[TBL] [Abstract][Full Text] [Related]
16. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Samoilova O; Novak J; Ben-Yehuda D; Strugov V; Gill D; Gribben JG; Hsu E; Lih CJ; Zhou C; Clow F; James DF; Styles L; Flinn IW
Lancet Oncol; 2019 Jan; 20(1):43-56. PubMed ID: 30522969
[TBL] [Abstract][Full Text] [Related]
17. Role of interferon alpha-2b, chlorambucil and prednisone in the treatment of chronic lymphocytic leukemia.
Molica S
Eur J Haematol; 1992 Feb; 48(2):117-8. PubMed ID: 1547874
[No Abstract] [Full Text] [Related]
18. Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.
Shah A
Ann Pharmacother; 2014 Oct; 48(10):1356-61. PubMed ID: 25037849
[TBL] [Abstract][Full Text] [Related]
19. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia.
Dighiero G; Maloum K; Desablens B; Cazin B; Navarro M; Leblay R; Leporrier M; Jaubert J; Lepeu G; Dreyfus B; Binet JL; Travade P
N Engl J Med; 1998 May; 338(21):1506-14. PubMed ID: 9593789
[TBL] [Abstract][Full Text] [Related]
20. Obinutuzumab (Gazyva) for chronic lymphocytic leukemia.
Med Lett Drugs Ther; 2014 Nov; 56(1455):e114-5. PubMed ID: 25538980
[No Abstract] [Full Text] [Related]
[Next] [New Search]
